摘要
目的:探讨ERβ和ERK1/2在卵巢上皮性癌组织中的表达及其相关性。方法:采用RT-PCR检测70例卵巢上皮性癌、24例卵巢良性肿瘤、24例正常卵巢组织中ERβ和ERKl/2 mRNA的表达,并分析其与临床病理特征之间的关系及两者的相关性。结果:卵巢上皮性癌组织中ERβ阳性表达率为55.7%,显著低于卵巢良性肿瘤(91.7%)及正常卵巢组织(100.0%),P<0.05;ERK1与ERK2的阳性表达率分别为85.7%和85.7%,显著高于卵巢良性肿瘤(50.0%和50.0%)及正常卵巢组织(33.3%和33.3%),P<0.05;卵巢良性肿瘤与正常卵巢组织相比,ERβ和ERK1/2表达差异无统计学意义,P>0.05。ERβ阳性表达率与组织学类型、组织分化程度及淋巴转移相关,P<0.05;与患者年龄、FIGO分期及腹水无关,P>0.05。ERK1/2阳性表达率与组织分化程度、FIGO分期和腹水相关,P<0.05;与患者年龄、组织学类型及淋巴转移无关,P>0.05。在卵巢上皮性癌组织中,ERβ和ERK1/2表达呈负相关,r值分别为-0.743和-0.832,P值分别为0.009和0.001。结论:卵巢上皮性癌组织中ERβ表达的降低和ERK1/2的过高表达可能在卵巢癌发生、发展和侵袭中有协同作用,这可能为卵巢癌的预后和内分泌治疗提供新的靶点和方向。
OBJECTIVE： To investigate the expression and relationship of ERβ and ERK1/2 in epithelial ovarian cancer. METHODS： The mRNA expression of ERβ and ERK1/2 were evaluated using reverse transcription-polymerase chain reaction （RT-PCR） in 70 epithelial ovarian cancers, 24 benign ovarian tumors and 24 normal ovarian tissues. Their relationship and clinical pathological characters were also analyzed. RESULTS： The positive rate of ERβ in patients with epithelial ovarian cancers was 55.7 % （39/70）, which was significantly lower than that in benign ovarian tumors （91.7 %） and normal controls（100.0% ,P〈0.05）. The positive rates of ERK1 and ERK2 in ovarian cancer were 85.7% and 85.7% respectively, significantly higher than that in benign ovarian tumors （50. 0%, 50. 0%） and normal controls （33. 3%, 33.3% ,P〈0.05）. However,both ERK1 and ERK2 had no statistical difference between benign ovarian tumors and normal ovarian tissues （P〉0.05）. Expression of ERI3 was closely related to histologic types, pathologic grades and lymph node metastasis （P〈0.05）, but it showed no relationship with ages, FIGO stages and hydroperitoneum （P〉0.05）. ERK1/2 was associated to pathologic grades,FIGO stages and hydroperitoneum （P^0. 05） ,but no relationship with ages and histologic types （P〉0.05）. Expression of ERβ was negatively correlated with expression of ERK1/2 in epithelial ovarian cancers （r= -0.743, P= 0. 009 ; r= - 0. 832, P = 0. 001 ）. CONCLUSIONS： The abnormal expression of ERβ and ERK1/2 play important and synergetic roles in the occurrence and development of ovarian carcinoma. ERβ can be an im- portant biomarker for monitoring the prognosis of ovarian cancer, and may also be a potiential target in the endocrine treatment of ovarian cancer.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2013年第3期206-209,213,共5页
Chinese Journal of Cancer Prevention and Treatment
关键词
卵巢肿瘤
雌激素受体8
细胞外信号调控激酶1
2
聚合酶连反应
epithelial ovarian neoplasms
ERβ
extracellular signal-regulated kinase 1/2
polymerase chain reaction
